卡瑞利珠单抗联合阿帕替尼治疗肝细胞癌临床应用专家共识OA

Camrelizumab combined with apatinib has been approved by the National Medical Products Administration(NMPA)as a first-line therapeutic regimen for hepatocellular carcinoma(HCC),and a wealth of clinical research evidence and practical experience associated with liver cancer has been accumulated to date.To guide the rational and effective clinical administration of camrelizumab combined with apatinib for HCC treatment,Expert Committee for Liver Cancer and Expert Committee on Safety Management of Anti-Tumor Drugs,Chinese Society of Clinical Oncology,jointly organized multidisciplinary experts and scholars specializing in liver cancer and related disciplines nationwide.This expert consensus has been formulated after thorough discussions and repeated revisions,in order to provide standardized and evidence-based clinical guidance for clinicians.